Current Treatment Options in Oncology

, Volume 6, Issue 3, pp 229–240

Current status of stem cell transplantation for multiple myeloma

  • Morie A. Gertz
  • Martha Q. Lacy
  • Angela Dispenzieri
  • Suzanne Hayman
Article

DOI: 10.1007/s11864-005-0006-1

Cite this article as:
Gertz, M.A., Lacy, M.Q., Dispenzieri, A. et al. Curr. Treat. Options in Oncol. (2005) 6: 229. doi:10.1007/s11864-005-0006-1

Opinion statement

Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Morie A. Gertz
    • 1
  • Martha Q. Lacy
  • Angela Dispenzieri
  • Suzanne Hayman
  1. 1.Division of Hematology and Internal MedicineMayo ClinicRochesterUSA

Personalised recommendations